Founders and Management team
Dr Thierry Sulpice, PhD
Founder, Chairman, CEO and CSO
Dr Sulpice is a pharmacologist and has extensive management experience within the biopharmaceutical industry.
Dr Sulpice has over 20 years experience and is the founder and managing director of two preclinical research organizations worldwide. Prior to these positions, he was head of the Cardiovascular and Metabolic diseases pharmacology unit in the Discovery Department at Sanofi, where he led drug discovery optimization and preclinical development for projects targeting the cardiometabolic syndrome. He earned his PhD in “Pharmacology and cellular physiology of cardiac cells” at the University of Grenoble, France.
Dr Caroline Dubroca, PhD
Head of Preclinical Platform
Dr Dubroca has 10 years of experience in non-clinical pharmacology within both academic research and private companies. Being involved in drug discovery and development process she gained industry know-how and a thorough knowledge of cardiovascular and metabolic issues.
Dr Dubroca’s research focused on heart failure, pathological cardiac hypertrophy and vascular mechanotransduction including flow (shear stress)-mediated dilation.
She earned her PhD under the leadership of Dr Henrion, in Dr Tedgui’s unit of “Biology and Pharmacology of haemostasis and vessels” at Paris VII University. She led her post-doctoral research in Dr Balligand ‘s unit of Pharmacology and Therapeutics at the Catholic University of Louvain, Belgium.
Pr Atul Pathak, MD, PhD
Pr Atul Pathak is a Pharmacologist and Cardiologist. He leads a clinical research team focused on cardiovascular pathophysiology and clinical pharmacology and is affiliated to INSERM (National Institute of Medical Research).
He is a consultant in Clinical Cardiology within the Cardiometabolic department at Toulouse University Hospital. He focuses on the care of patients with cardiovascular risk factors (metabolic and cardiovascular) and their consequences, such as heart failure.
His research interests are: (i) new diagnostic tools and treatment of cardiometabolic risk factors and heart failure, (ii) the human sympathetic nervous system, (iii) neurotransmitters of the neuro cardiac synapse and generally clinical pharmacology of cardiovascular diseases. He currently leads both a clinical and an experimental team working on the nervous regulation of cardiovascular function and, more particularly, the role of the autonomic nervous system in the control of arterial pressure, cardiac rhythm and contraction, and associated diseases (i.e. obesity, diabetes).
Pr Pathak obtained his MD at the Faculty of Medicine and a European PhD in Clinical and Experimental Pharmacology in Toulouse, France. He led his post-doctoral research in the Department of Cardiology at Hospital Erasme and Free University of Bruxelles, Belgium.
Pr Pathak has been awarded by the ESC (Young Investigator Award), the British Pharmacological Society and the French Society of Cardiology. He is also a member of the French Association of Pharmacologists, the French Society of Hypertension and Cardiology and the American Society for Heart Failure. He was elected President of the Cardiovascular Pharmacology Working Group of the French Society of Cardiology.
Pr Jean Michel Senard, MD, PhD
Pr Jean-Michel Senard, is a Pharmacologist specializing in Cardiac & Cardiovascular Systems and Neurosciences.
He is head of the “Molecular and Clinical Pharmacology of the autonomic nervous system” team at the Rangueil Institute of Molecular Medicine, part of INSERM and Paul Sabatier University, in Toulouse.
The research projects of his team concern molecular and clinical determinants of sympathetic activity and cardiac architecture. The translational projects include:
- the pharmacology of noradrenaline release by GPCRs of sympathetic nerve endings
- the use of biophysical methods based on energy transfer (BRET)
- the role of cardiac cells on the function of sympathetic nerve endings
- the identification and functional characterization of proteins involved in cardiac cells
These projects aim to enable a better understanding of the mechanisms involved in the modulation of neurocardiac synapse activity which underly the importance of retrograde remodeling and explaining the effect of the heart on the autonomic nervous system. They also aim to identify new drugs with optimized pharmacological properties that need to be verified in a clinical setting.
Pr Senard also serves as the medical head of the Unit of Clinical Neuropharmacology and of the Laboratory of Autonomic Nervous System at Toulouse Hospital. Pr Senard obtained his MD and PhD in Pharmacology in Toulouse, France. He is a member of the French Society of Pharmacology and Clinical Pharmacology, the French society of Cardiology and Hypertension and the European Federation of Autonomic Societies (EFAS).